SLS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
10.6M
+14.9%
9.3M
+12.1%
8.3M
+16.5%
7.1M
+3.1%
6.9M
R&D
6.3M
+22.3%
5.1M
+8.4%
4.7M
+12.2%
4.2M
+8.9%
3.9M
SG&A
4.4M
+5.7%
4.1M
+17.0%
3.5M
+23.0%
2.9M
-4.5%
3.0M
Operating Income
-10629000
-14.9%
-9252000
-12.1%
-8255000
-16.5%
-7083000
-3.1%
-6873000
EBITDA
-10629000
-14.9%
-9252000
-12.1%
-8255000
-16.5%
-7083000
-3.1%
-6873000
Net Income
-9605000
-14.3%
-8407000
-9.8%
-7658000
-12.8%
-6791000
-2.9%
-6601000
EPS (Basic)
$-0.05
+0.0%
$-0.05
+0.0%
$-0.05
+16.7%
$-0.06
+14.3%
$-0.07
EPS (Diluted)
$-0.05
+0.0%
$-0.05
+0.0%
$-0.05
+16.7%
$-0.06
+14.3%
$-0.07
Shares (Diluted)
189.2M
+9.7%
172.5M
+21.9%
141.5M
+30.5%
108.4M
+10.0%
98.6M
SELLAS Life Sciences (SLS) โ€” Financials